Incidence-based mortality for the most common U.S. lung cancer fell about 6% per year between 2013 and 2016 as treatment advances accelerated previous declines, according to a study reported this week in the New England Journal of Medicine.

“This analysis shows for the first time that nationwide mortality rates for the most common category of lung cancer, non-small cell lung cancer, are declining faster than its incidence, an advance that correlates with the U.S. Food and Drug Administration approval of several targeted therapies for this cancer in recent years,” said Douglas Lowy, M.D., National Cancer Institute deputy director and co-author of the study.

Related News Articles

Headline
Adults should be screened for colon cancer beginning at age 45 rather than 50, even in the absence of symptoms and personal or family history related to…
Headline
The AHA Oct. 21 at noon ET will host a webinar featuring leaders from Henry Ford Health System, Ascension Wisconsin and Loyola University Chicago’s Stritch…
Headline
Hospital and health system trustees are promoting value in their communities by tackling societal factors that influence the health and well-being of residents…
Headline
The Department of Health and Human Services and the Steven and Alexandra Cohen Foundation Oct. 10 announced the LymeX Innovation Accelerator, a $25 million,…
Headline
U.S. Surgeon General Jerome Adams, M.D., yesterday released a report urging Americans to recognize and address hypertension control as a national public health…
Headline
The AHA and Aligning for Health Sept. 24 hosted a webinar detailing how hospitals and health systems are working to better identify and address health, social…